Viewing Study NCT06284460

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-25 @ 2:06 AM

Ignite Modification Date: 2025-12-26 @ 5:54 AM

Study NCT ID: NCT06284460

Status: WITHDRAWN

Last Update Posted: 2024-10-24

First Post: 2024-02-21

Is NOT Gene Therapy: True

Has Adverse Events: False

Brief Title: Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Sponsor: M.D. Anderson Cancer Center

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module